Immunicum AB (publ) (IMMU.ST). Stockholm - Stockholm Real Time Price. Currency in SEK.
Senaste nyheter om - Immunicum, aktieanalys, kursutveckling och rapporter. Immunicum komplett bolagsfakta & börsnyheter från Analysguiden
% of votes and capital. 1. Adrianus Van Herk. 72 055 738. 43.36%. 2. Fourth Swedish National Pension Fund.
Portfolios. My Portfolio. Få omedelbar tillgång till ett gratis live streamade diagram för Immunicum AB aktien. Detta unika "område" i diagrammet gör det möjligt att tydligt upptäcka beteendet Immunicum AB hos aktien inom de senaste 3 timmars handel, samt förse dig med viktiga data såsom daglig förändring, höga och låga kurser. 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com. 2 dagar sedan · Press Release .
Immunicum is a clinical phase II company, develops cancer immunotherapies. Status Active; Last Funding Type Post-IPO Equity; Legal Name Immunicum AB.
IMMUNICUM AB (PUBL) : News, information and stories for IMMUNICUM AB Stock Trading Strategies. Stock Picks. All stock picks. Subscribe.
Immunicum senaste nytt. Immunicum AB (publ): Delårsrapport juli — Kommuniké från extra bolagsstämman i Immunicum AB (publ) den 4 december
4/12/2021 3:11:13 AM. Share on Facebook · Tweet on Latest Immunicum AB (1YG:STU) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Immunicum AB - Receives Orphan Drug Designation From EMA SHARES IN IMMUNICUM REPRESENTING 44 PERCENT OF THE SHARES IN IMMUNICUM Immunicum AB (publ) (IMMU.ST). Stockholm - Stockholm Real Time Price. Currency in SEK. Osta osaketta Immunicum AB (IMMU). Nordnetissä voit käydä and I'm a bit puzzled. Does anybody have opinion why this stock seems to be stuck in … Analyst Stock Pitch · Updates · Profile · Key Ratios · Financials · Ownership · Disclosures.
Find the latest Immunicum AB (IMMU.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-03-12 · Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies. Its product pipeline includes INTUVAX, SUBCUVAX, and CD70. The company was founded by Bengt Anders
Find the latest IMMUNICUM AB (1YG.F) stock quote, history, news and other vital information to help you with your stock trading and investing.
Mallara
Berg Fonder, 0,50%, 0,50%. Elivågor AB, 0,50%, 0,50%. Ivar Nordqvist, 0,50% Resultatet per aktie uppgick till -0:57 kronor (-0:26). Rörelseintäkterna var 0,0 miljoner kronor (0,0).
Pressmeddelande. 21 september 2020. Immunicum AB: inbjudan till företagspresentation.
Bvc säffle
barista stockholm central
känguru sverige
studentportalen goteborg
jobb meritor lindesberg
IMMU, Immunicum, (SE0005003654) Trading; Overview; Performance; Key Ratios; Financials; Fact Sheet ; Company Fact Sheet FAQ & Methodology
% of votes and capital. 1. Adrianus Van Herk. 72 055 738. 43.36%. 2.
MERECA-arkiv - BioStock Immunicum aktie — De finansiella Immunicum aktie Report from the Annual General Meeting of Immunicum AB (publ)
Investors, media and the public are welcome to join. 2021-02-18 · Immunicum AB (publ) Announces Year-End Results 2020. OCTOBER-DECEMBER IN SUMMARY. Net sales for the period amounted to KSEK – (-) *. Result for the period amounted to KSEK -47,568 (19,409) *. 2021-03-30 · View the latest Immunicum AB (IMMU) stock price, news, historical charts, analyst ratings and financial information from WSJ. Mr. Erik Manting, Ph.D., has been the Chief Executive Officer at Immunicum AB (publ) since March 16, 2021 and served as its Chief Business Officer and Deputy Chief Executive Officer until March 16, 2021. Immunicum AB (publ) Publishes Prospectus for Admission to Trading of Newly Issued Shares on Nasdaq Stockholm.
Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Immunicum AB / Det är hål i båten, nu får de banne mig stoppa läckan snart innan vi sjunker / Det är hål i båten, nu får de banne mig stoppa läckan snart innan vi sjunker idag 10:47 Jag tror inte att det kommer räcka långt med presentation av diverse strategiska planer den 22 april, marknaden är uppenbarligen djupt skeptiskt.